Department of Pharmacology and Toxicology, Maastricht University, 6200 MD Maastricht, The Netherlands.
NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, 6200 MD Maastricht, The Netherlands.
Nutrients. 2021 Oct 21;13(11):3707. doi: 10.3390/nu13113707.
Supplementation with nicotinamide adenine dinucleotide (NAD) precursors including dietary nicotinamide has been found to boost tissue NAD levels and ameliorate oxidative stress-induced damage that contributes to aging and aging-related diseases. The association between dietary NAD precursors and patient-reported health-related outcomes in cancer survivors has not been investigated. This study aimed to determine associations of dietary nicotinamide intake with different patient-reported outcomes in colorectal cancer survivors, 2 to 10 years post-diagnosis. A total of 145 eligible participants were recruited into this cross-sectional study. Dietary nicotinamide intake level was calculated based on data from 7-day food diaries. Fatigue was assessed with the Checklist Individual Strength (CIS), which is a subscale of the cancer-specific European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC), and anxiety and depression were assessed with Hospital Anxiety and Depression Scale (HADS). Oxidative stress marker serum protein carbonyl contents and serum NAD levels were measured. A hierarchical linear regression model with confounder adjustment was performed to analyze the association of nicotinamide intake, serum protein carbonyl contents, and NAD levels with patient-reported outcomes. The median values of daily nicotinamide intake for male and female participants were 19.1 and 14.4 mg, respectively. Daily dietary nicotinamide intake was associated with a lower level of fatigue (β: -14.85 (-28.14, -1.56)) and a lower level of anxiety and depression (β: -4.69 (-8.55, -0.83)). Subgroup analyses by sex showed that a beneficial association between nicotinamide intake and patient-reported outcomes was mainly found in men. To conclude, our findings suggested that higher dietary NAD precursor nicotinamide intake was cross-sectionally associated with less patient-reported outcomes in CRC survivors.
补充烟酰胺腺嘌呤二核苷酸（NAD）前体，包括饮食中的烟酰胺，已被发现可提高组织 NAD 水平，并改善氧化应激诱导的损伤，而氧化应激损伤与衰老和与衰老相关的疾病有关。饮食 NAD 前体与癌症幸存者的患者报告的健康相关结局之间的关联尚未得到研究。本研究旨在确定结直肠癌幸存者诊断后 2 至 10 年内，饮食中烟酰胺的摄入量与不同患者报告的结局之间的关联。共有 145 名符合条件的参与者被纳入这项横断面研究。根据 7 天食物日记的数据计算饮食中烟酰胺的摄入量。疲劳通过癌症特异性欧洲癌症研究与治疗组织生活质量问卷核心 30 分（EORTC）的子量表 Checklist Individual Strength（CIS）进行评估，焦虑和抑郁通过医院焦虑和抑郁量表（HADS）进行评估。氧化应激标志物血清蛋白羰基含量和血清 NAD 水平进行了测量。进行了层次线性回归模型分析，调整混杂因素后分析了烟酰胺摄入量、血清蛋白羰基含量和 NAD 水平与患者报告结局的关系。男性和女性参与者的每日烟酰胺摄入量中位数分别为 19.1 和 14.4mg。每日饮食烟酰胺摄入量与疲劳程度降低（β：-14.85（-28.14，-1.56））和焦虑和抑郁程度降低有关（β：-4.69（-8.55，-0.83））。按性别进行的亚组分析表明，烟酰胺摄入量与患者报告结局之间的有益关联主要在男性中发现。总之，我们的研究结果表明，较高的饮食 NAD 前体烟酰胺摄入量与 CRC 幸存者的患者报告结局呈横断面负相关。
